Please Wait
Applying Filters...
menu
    • menu
    Suanfarma, at the Core of a Better Life.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-01-20

    Virtual Booth

    Contact Supplier

    Menu

    Lazertinib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    $ API Ref.Price (USD/KG) : 317,623Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    EU clears J&J's Rybrevant,Lazcluze duo for first-line lung cancer
    EU clears J&J's Rybrevant,Lazcluze duo for first-line lung cancer

    31 Dec 2024

    // PRESS RELEASE

    https://www.jnj.com/media-center/press-releases/european-commission-approves-rybrevant-amivantamab-in-combination-with-lazcluze-lazertinib-for-the-first-line-treatment-of-patients-with-egfr-mutated-advanced-non-small-cell-lung-cancer

    PRESS RELEASE
    31 Dec 2024
    Share Share
    European Commission Approves Rybrevant & Lazcluze Combo for NSCLC
    European Commission Approves Rybrevant & Lazcluze Combo for NSCLC

    30 Dec 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/12/30/3002463/0/en/European-Commission-approves-RYBREVANT-amivantamab-in-combination-with-LAZCLUZE-lazertinib-for-the-first-line-treatment-of-patients-with-EGFR-mutated-advanced-non-small-cell-lung-c.html

    GLOBENEWSWIRE
    30 Dec 2024
    Share Share
    CHMP Recommends Rybrevant & Lazcluze® for EGFR-mutant NSCLC
    CHMP Recommends Rybrevant & Lazcluze® for EGFR-mutant NSCLC

    15 Nov 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/11/15/2982110/0/en/CHMP-recommends-RYBREVANT-amivantamab-in-combination-with-LAZCLUZE-lazertinib-for-the-first-line-treatment-of-patients-with-EGFR-mutated-advanced-non-small-cell-lung-cancer.html

    GLOBENEWSWIRE
    15 Nov 2024
    Share Share
    J&J Bolsters Rybrevant-Lazcluze Case Vs AZ's Tagrisso With Survival Data
    J&J Bolsters Rybrevant-Lazcluze Case Vs AZ's Tagrisso With Survival Data

    09 Sep 2024

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/jj-bolsters-rybrevant-lazcluzes-case-against-azs-tagrisso-nominal-survival-win

    FIERCE PHARMA
    09 Sep 2024
    Share Share
    RYBREVANT Plus Lazertinib Shows Survival Trend In Lung Cancer
    RYBREVANT Plus Lazertinib Shows Survival Trend In Lung Cancer

    08 Sep 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/09/08/2942454/0/en/RYBREVANT-amivantamab-plus-lazertinib-show-strong-favourable-overall-survival-trend-versus-osimertinib-in-EGFR-mutated-advanced-lung-cancer.html

    GLOBENEWSWIRE
    08 Sep 2024
    Share Share
    LAZCLUZE Now Available From Onco360 For Metastatic NSCLC Treatment
    LAZCLUZE Now Available From Onco360 For Metastatic NSCLC Treatment

    30 Aug 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/08/30/2938443/0/en/LAZCLUZE-lazertinib-Now-Available-from-Onco360-for-the-First-line-Treatment-in-Combination-with-Rybrevant-of-Adult-Patients-with-Metastatic-Non-Small-Cell-Lung-Cancer-Whose-Tumors-.html

    GLOBENEWSWIRE
    30 Aug 2024
    Share Share